Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684898 | 0.87 | CNR1 (0.55) | CNR1NR1H4PRKAA2CNR2 | |
| SCHEMBL4679409 | 0.85 | CNR1 (1.00) | CNR1NR1H4DYRK1APDE4BPDE4C | |
| SCHEMBL4677708 | 0.79 | CNR1 (0.74) | CNR1NR1H4PRKAA2DYRK1APDE4B | |
| SCHEMBL4680959 | 0.78 | PTGDR2 (0.42) | CNR1MDM2 | |
| SCHEMBL4684112 | 0.78 | CNR1 (0.70) | CNR1NR1H4DYRK1APDE4BPDE4C | |
| SCHEMBL4677242 | 0.78 | CNR1 (0.46) | CNR1TP53 | |
| SCHEMBL4676257 | 0.76 | CNR1 (0.69) | CNR1NR1H4DYRK1APDE4BPDE4C | |
| SCHEMBL4681163 | 0.74 | CNR1 (0.67) | CNR1NR1H4CNR2DYRK1APDE4B | |
| SCHEMBL4676935 | 0.71 | CNR1 (0.62) | CNR1NR1H4CNR2DYRK1APDE4B | |
| SCHEMBL5769982 | 0.70 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | claimed |
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1638953-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004111034-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | CNR1 2/4885NR1H4 960/4885PRKAA2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.